论文部分内容阅读
目的观察自体造血干细胞移植（AHSCT）治疗恶性血液病和晚期肺癌（ALC）的疗效。方法5例急性白血病（AL）、1例霍奇金病（HD）和1例晚期肺癌（ALC）用AHSCT治疗。其中6例接受自体外周血干细胞移植（APBSCT），1例接受自体骨髓移植（ABMT）。AL和HD均在初次完全缓解后移植，ALC患者在化疗后获部分缓解后移植。AL、HD和ALC分别用MAC方案、MeVEC方案和MeVAM方案预处理。结果7例患者移植后均获造血重建；5例AL和1例HD已分别持续完全缓解450天、313天、276天、112天、81天和171天；1例则ALC患者在移植后完全缓解115天后出现颅内复发。结论初步结果提示AHSCT能延长AL、HD和ALC患者的无病存活期。
Objective To observe the efficacy of autologous hematopoietic stem cell transplantation (AHSCT) in the treatment of hematological malignancies and advanced lung cancer (ALC). Methods Five cases of acute leukemia (AL), one case of Hodgkin’s disease (HD) and one case of advanced lung cancer (ALC) were treated with AHSCT. Six of them received autologous peripheral blood stem cell transplantation (APBSCT) and one received autologous bone marrow transplantation (ABMT). Both AL and HD were transplanted after the initial complete remission, and ALC patients were partially transplanted after chemotherapy. AL, HD, and ALC are preprocessed using the MAC scheme, MeVEC scheme, and MeVAM scheme, respectively. Results All 7 patients received hematopoietic reconstitution after transplantation; 5 patients with AL and 1 patient with HD had sustained complete remission of 450 days, 313 days, 276 days, 112 days, 81 days, and 171 days; 1 patient had ALC completely after transplantation. 115 days after remission, intracranial recurrence occurred. Conclusion Preliminary results suggest that AHSCT can prolong disease-free survival in patients with AL, HD, and ALC.